Small study checks safety of fabry drug replagal in indian patients

NCT ID NCT05067868

Recruiting now Disease control Sponsor: Shire Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing the safety of Replagal, an enzyme replacement therapy, in 5 Indian children and adults with Fabry disease who have not taken it before. Participants receive an infusion every 2 weeks for about a year. The main goal is to track side effects and serious reactions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Replagal (agalsidase alfa), an enzyme replacement therapy
What this could lead to: If successful, this study could confirm that Replagal is safe for Indian patients with Fabry disease, supporting its continued use as a treatment.
What could go wrong: This is a very small study (5 people) with no comparison group, so results may not apply to everyone. It focuses on safety, not whether the drug works well.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FABRY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Fabry disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FABRY DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

All India Institute of Medical Sciences (AIIMS)
RECRUITING

New Delhi, 110029, India
Institute of Child Health
NOT_YET_RECRUITING

Kolkata, 700017, India
Sir Gangaram Hospital
RECRUITING

New Delhi, 110060, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.